Latest Acquisition Sees ProductLife Group Expand its Asia-Pacific Footprint
ProductLife Group has announced its acquisition of Australian company Commercial Eyes.
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - stock.adobe.com
ProductLife Group (PLG), a specialized provider of regulatory, scientific, quality, and digital transformation consulting services for the life sciences industry, announced in a Feb. 1, 2024 press release its acquisition of Australian company Commercial Eyes.
Commercial Eyes is a pharmaceutical and medical device commercialization company that specializes in regulatory affairs, pharmacovigilance, medical information, quality assurance, market access, market research, and patient programs. Through the acquisition, PLG will be able to combine its global presence and expertise with the regional knowledge and capabilities of Commercial Eyes to be able to deliver enhanced services and solutions to clients.
“Joining PLG is a major strategic move for Commercial Eyes, our people, and our clients. We will leverage the platform we have created over the last 22 years to expand our footprint globally,” said Andrew Carter, founder and managing director of Commercial Eyes in the press release. “This [expansion] will create significant professional development opportunities for our team members and enable us to better support our clients with global coverage of end-to-end life sciences consulting services.”
“This merger not only enables us to broaden our geographical footprint and expand our offerings to global markets but also empowers us to better serve our clients throughout their market and patient access strategy. The acquisition of Commercial Eyes marks an exciting new chapter in our journey. Together, we possess the collective strength, expertise, and passion to drive positive change and shape the future of the life sciences industry,” added Xavier Duburcq, CEO of PLG in the press release. “Our two companies share similar values: pioneering the way for innovation, client satisfaction, team spirit and a unique sense of purpose for life sciences. This common set of values forms a solid foundation for the seamless integration of the two organizations.”
Source: PLG
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
